Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of TransEnterix Inc (NYSE: TRXC) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of TransEnterix Inc (NYSE: TRXC) concerning whether a series of statements by TransEnterix Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On April 20, 2016, TransEnterix revealed that the Food and Drug Administration ("FDA") informed the Company on April 19, 2016, that it has determined that "SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission." 

On this news, TransEnterix shares were down more than 56% on intraday trading on April 21, 2016.

Based in North Carolina, and founded in 2006 TransEnterix Inc focuses on the development and commercialization of surgical robotic systems.

If you purchased shares of TransEnterix Inc (NYSE: TRXC) on or before April 20, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185